Generally, a high expression of nucleobindin-2/NESF-1 is associated with poor outcomes in breast, colon, bladder, prostate, gastric, renal, and endometrial cancer [16,17,18,19,20]. This evidence concerns the gene NUCB2 and endometrial cancer.